Advances in the diagnosis and management of colonic dysplasia in patients with inflammatory bowel disease

Shirley Cohen-Mekelburg, Yecheskel Schneider, Stephanie Gold, Ellen Scherl, Adam Steinlauf

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


The prevalence of colorectal cancer (CRC) in inflammatory bowel disease (IBD) is estimated at 3.7%. Risk factors for CRC include more severe disease (as reflected by the extent of disease and the duration of poorly controlled disease), family history of CRC, pseudopolyps, primary sclerosing cholangitis, and male sex. In addition, both early and late onset of IBD have been shown to be risk factors in different studies. Most societal guidelines recommend initiation of surveillance colonoscopy at 8 to 10 years after IBD symptom onset, followed by subsequent surveillance in 1-to 2-year intervals. A recent paradigm shift has led to a focus on targeted biopsies using high-definition colonoscopy or chromoendoscopy rather than traditional white-light endoscopy, as most dysplasia has proven to be visible with these advances in technology. With this shift, endoscopic resection of focal dysplasia, rather than early recommendation for colectomy, has become commonplace. Future studies should focus on newer methods of dysplasia detection, along with comparative effectiveness trials, to determine the optimal approach. Individual risk stratification may also prove beneficial in determining optimal surveillance strategies and intervals.

Original languageEnglish
Pages (from-to)357-362
Number of pages6
JournalGastroenterology and Hepatology
Issue number6
StatePublished - Jun 2017
Externally publishedYes


  • Carcinoma
  • Colonoscopy
  • Colorectal Cancer
  • Crohn's Disease
  • Surveillance
  • Ulcerative Colitis


Dive into the research topics of 'Advances in the diagnosis and management of colonic dysplasia in patients with inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this